Commercialising Disruptive Technology for Advanced therapies with Phacilitate and Invetech

Commercialising Disruptive Technology

A recorded panel discussion from Advanced Therapies connect, lead by Invetech and friends

This panel aired live at Phacilitate's first virtual event, Advanced Therapies Connect and examined the role of disruptive technology in commercialising advanced therapies.

The panellists review the whole journey from the back of the napkin to the bedside.

Here's your panel line up:
  • Kevin Alessandri, CEO/CTO, Treefrog Therapeutics
  • Vincent Ronfard, Chief Innovation Officer, CUTISS
  • Rob Schutte, Executive Director, Process Development, Humacyte
  • David Hodl, Vice President, Business Development, Cell Therapy, Invetech